BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR402663 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR402663\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06660667-5116@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:SAR402663: Phase 1/2 readout est. (NCT06660667)
DESCRIPTION:SAR402663\, phase 1/2\, Age-Related Macular Degeneration.\nStud
 y: A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovas
 cular Age-related Macular Degeneration\nEstimated primary completion: 18 M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sar402663#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066606
 67
URL:https://assetmemo.bio/drug/sar402663#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
